Dana-Farber’s Breast Oncology Center:
“Dr. Otto Metzger presented recent data on the PATINA Study.
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for HR+/HER-Positive.”
“PATINA study of induction THP > maintenance HP + ET +/- palbociclib in ER+HER2+ MBC.
Takeaway: after 6 cycles induction TH, patients can expect nearly 4 years of maintenance HP/ET/palbo on average before re-needing chemo/ADC!”
“PATINA trial
Palbociclib is making a comeback.
A practice-changing study in triple-positive breast cancer.”
“Otto Metzger presents the practice-changing results from the PATINA phase 3 trial: adding palbociclib to maintenance ET after 1 line THP for HR+/HER2+ MBC significantly and meaningfully improved PFS (44 vs 29 months, HR 0.74, p=0.007).
44 months!”
“Practice changing findings from PATINA presented by Otto Metzger.
- n=518 HR+/HER2+ mBC
- all received THP followed by HP+ET +/- palbociclib
- PFS was 29 vs 44 months with palbociclib
- Toxicity consistent with prior studies”
“PATINA significant and clinically important results. Collaboration between researchers. Congrats!”
“Amazingly presented by Otto Metzger at SABCS24:
PATINA Phase III trial testing Palbociclib + Anti-HER2 Therapy + ET vs. Anti-HER2 Therapy + ET in 1st-line HER2+ breast cancer maintenance.
- PFS: 29.1 vs. 44.3 months with Palbo (52-month follow-up).
- OS: Immature.”
“The AFT-38 PATINA phase III study demonstrates a clinically meaningful improvement of Palbociclib added to anti-HER2 and endocrine therapy in PFS among patients diagnosed with HR+/HER2+ breast cancer. How will this stand when we see the results of DB-09?”
“Making a critical point about how/why PATINA had such a high performance control arm, Dr. Sara Hurvitz describes how the recruitment window excluded patients who had a brisk progression, changing the shapes of the curves.”
Read the post “PATINA trial: Phase III Trial of Palbociclib, Anti-HER2 Therapy, and Endocrine Therapy vs. Anti-HER2 Therapy and Endocrine Therapy in HR+/HER2+ Metastatic Breast Cancer” on oncodaily.com.
